GEANT4 for breast dosimetry: parameters optimization study. (12th August 2015)

• Record Type: Journal Article
• Authors: Fedon, C; Longo, F; Mettivier, G; Longo, R
• Is Part Of: Physics in medicine & biology. Volume 60:Number 16(2015:Aug.)
• Page Start: N311
• Page End: N323
• Publication Date: 2015-08-12
• Subjects: breast dosimetry -- GEANT4 -- Monte Carlo code; Biophysics -- Periodicals; Medical physics -- Periodicals; 610.153
• DOI: 10.1088/0031-9155/60/16/N311
• Languages: English
• ISSNs: 0031-9155

Abstract

Abstract: Mean glandular dose (MGD) is the main dosimetric quantity in mammography. MGD evaluation is obtained by multiplying the entrance skin air kerma (ESAK) by normalized glandular dose (DgN) coefficients. While ESAK is an empirical quantity, DgN coefficients can only be estimated with Monte Carlo (MC) methods. Thus, a MC parameters benchmark is needed for effectively evaluating DgN coefficients. GEANT4 is a MC toolkit suitable for medical purposes that offers to the users several computational choices. In this work we investigate the GEANT4 performances testing the main PhysicsLists for medical applications. Four electromagnetic PhysicsLists were implemented: the linear attenuation coefficients were calculated for breast glandularity 0%, 50%, 100% in the energetic range 8–50 keV and DgN coefficients were evaluated. The results were compared with published data. Fit equations for the estimation of the G -factor parameter, introduced by the literature for converting the dose delivered in the heterogeneous medium to that in the glandular tissue, are proposed and the application of this parameter interaction-by-interaction or retrospectively is discussed. G4EmLivermorePhysicsList shows the best agreement for the linear attenuation coefficients both with theoretical values and published data. Moreover, excellent correlation factor ( ) is found for the DgN coefficients with the literature. The final goal of this study is to identify, for the first time, a benchmark of parameters that could be useful for future breast dosimetry studies with GEANT4.